Company Overview of Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. discovers and develops potential drugs for the treatment of breathing-control conditions associated with surgical anesthesia, drug-induced respiratory depression, pain management, and sleep apnea. It focuses on respiratory depression in the acute care market and sleep apnea in the chronic care market; and ventilator weaning, anesthetic/analgesic-induced respiratory depression, COPD, obesity-hypoventilation syndrome, and other diseases. The company was incorporated in 2003 and is based in Horsham, Pennsylvania.
213 Witmer Road
Horsham, PA 19044
Founded in 2003
Key Executives for Galleon Pharmaceuticals, Inc.
Founder and Strategic Advisor
Managing Partner of Morgenthaler Ventures
Chief Technology Officer and Vice President of Chemistry
Head of Bioanalytical Chemistry & DMPK
Compensation as of Fiscal Year 2015.
Galleon Pharmaceuticals, Inc. Key Developments
Galleon Pharmaceuticals Names Joseph Oliveto as Chief Executive Officer
Aug 4 15
Galleon Pharmaceuticals announced that it has named Joseph Oliveto as Chief Executive Officer, effective immediately. Mr. Oliveto replaces James C. Mannion, Ph.D., who will retire as CEO and continue to serve as a strategic advisor to the company. Mr. Oliveto brings more than 25 years of pharmaceutical and biotech experience across the areas of drug development, commercialization, manufacturing and business development. Most recently, Mr. Oliveto served as President and CEO of Chelsea Therapeutics, a publicly held biopharmaceutical company. During his tenure as CEO, he led the company through the FDA’s approval of Northera™ for the treatment of neurogenic orthostatic hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc.
Galleon Pharmaceuticals Announces Publication of Proof-of- Concept Clinical Studies for GAL-021, Projected Use for the Emerging Perioperative Sleep Apnea Epidemic
Sep 2 14
Galleon Pharmaceuticals announced clinically and statistically significant (p<0.01) results from a double-blind, placebo-controlled clinical proof-of-concept study of its lead investigational compound GAL-021 in normal volunteers. The data were published in the most recent issue of Anesthesiology. The study sought to assess whether GAL-021 stimulated breathing in humans with respiratory depression induced by a potent opioid under conditions common after surgery. Researchers concluded that GAL-021 met or exceeded the study's pre-defined goals of maintaining both respiration and pain control under these conditions, and called for further clinical exploration of the drug's safety and efficacy. GAL-021 is being developed to prevent respiratory complications in surgical patients, including those at higher risk due to sleep apnea. According to a recent report in the New England Journal of Medicine, 25% to 80% of surgical patients have sleep apnea predisposing them to the rapidly emerging perioperative sleep apnea epidemic. The combination of sleep apnea with respiratory depressant drugs such as opioids, sedatives and anesthetics is especially dangerous and complicates care of these patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries